Table 1 List of prospective RCTs that evaluated the employment of anti-VEGF T&E regimens in nAMD patients
Study Name | # of Eyes | Agent | Study Duration | Initial Dose | Extension / Shortening Interval | Min/Max Interval | VA Gain at 1 yr /2 yrs | # of Injection in 1 yr/ Through 2 yrs | % of Pts Achieved Treatment Internal ≥ 12 wks |
|---|---|---|---|---|---|---|---|---|---|
TREND [13] | 323 | IVR | 1 yr | Monthly injections until dry macula is achieved | +/− 2 wks | 4/12 wks | 6.2/n.a. | 8.7/n.a. | 22.3/n.a. |
TREX-AMD [16] | 40 | IVR | 2 yrs | 3 monthly injections | +/− 2 wks | 4/12 wks | 10.4/8.7 | 10.1/18.6 | n.a./n.a |
CANTREAT [17] | 287 | IVR | 2 yrs | 3 monthly injections | +/− 2 wks | 4/12 wks | 8.4/6.8 | 9.4/17.6 | n.a./n.a. |
431 | IVR | 2 yrs | monthly injections until dry macula is achieved | +/− 2 wks | 4/12 wks | 8.7/7.4 | 8.0/16.0 | 17.0/n.a. | |
IVB | 8.4/6.6 | 8.9/18.2 | 10.0/n.a. | ||||||
FLUID [20] | 349 | IVR | 2 yrs | 3 monthly injections | +/− 2 wks | 4/12 wks | 4.0/3.0 | 9.5/17.0 | n.a. |
4.3/2.6 | 8.9/15.8 | n.a. | |||||||
RIVAL [21] | 281 | IVR | 2 yrs | 3 monthly injections | +/− 2 wks | 4/12 wks | 6.9/6.5 | 9.7/17.7 | n.a. |
IVA | 5.2/5.3 | 9.7/17.0 | n.a. | ||||||
ALTAIR [22] | 255 | IVA | 2 yrs | 3 monthly injections | +/− 2 wks +/− 4 wks | 8/16 wks | 9.0/7.6 | 7.2/10.4 | 56.8/56.9 |
8.4/6.1 | 6.9/10.4 | 57.8/60.2 | |||||||
ARIES [23] | 135 | IVA | 2 yrs | 3 monthly injections | +/− 2 wks | 8/16 wks | 6.8/4.3 | 7.1/12.0 | n.a./47.2 |